Results 51 to 60 of about 224,020 (260)

Kaposi's sarcoma in a patient with erythroblastopenia and thymoma: Reactivation after topical corticosteroids [PDF]

, 1998
We report a 69-year-old female with erythroblastopenia and thymoma who developed lesions of Kaposi's sarcoma (KS) after thymectomy, 2 months after the initiation of therapy with methylprednisolone.
Alomar, A., Barnadas, M. A., Curell, R., de Moragas, J. M., Garcia-Patos, V., Kind, P., Pedro, C., Perez, E., Sander, C. A.   +8 more
core   +1 more source

In vitro models of cancer‐associated fibroblast heterogeneity uncover subtype‐specific effects of CRISPR perturbations

Molecular Oncology, EarlyView.
Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra, Shamsudheen Karuthedath Vellarikkal, Lixia Li, Hong Sun, Khoa Nguyen, Amber Montano, Suchitra Natarajan, Federica Piccioni, Alex Michael Tamburino, Xin Yu, Aleksandra Katarzyna Olow   +10 more
wiley   +1 more source

Effect of interferon-alpha on experimental septal fibrosis of the liver - study with a new model

Memorias do Instituto Oswaldo Cruz, 2001
Interferon-alpha is used in antiviral therapy in humans, mainly for viral hepatitis B and C. An anti-fibrotic effect of interferon has been postulated even in the absence of anti-viral response, which suggests that interferon directly inhibits ...
Marcia Maria de Souza, Raymundo Paraná, Christian Trepo, Aryon A Barbosa Jr, Irismar Oliveira, Zilton A Andrade   +5 more
doaj   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

Clinics, 2012
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal, Nailu Angélica Sinicato, Karina Oliveira Peliçari, Roberto Marini, Lilian Tereza Lavras Costallat, Simone Appenzeller   +5 more
doaj  

Tratamento clínico do linfangioma com alfa-2a-interferon Treatment of lymphangioma with interferon-alpha-2a

Jornal de Pediatria, 2001
OBJETIVO: descrever os resultados obtidos com o uso do alfa-2a-interferon no tratamento de pacientes pediátricos com linfangiomas irressecáveis ou refratários a outros tratamentos.
Reynaldo J.S.P. de Souza, Luiz G. Tone
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus

Clinics, 2012
OBJECTIVE: To determine the serum levels of interferon alpha in childhood-onset systemic lupus erythematosus patients, their first-degree relatives and healthy controls and to evaluate the associations between serum interferon alpha and disease activity,
Mariana Postal, Nailu Angélica Sinicato, Karina Oliveira Peliçari, Roberto Marini, Lilian Tereza Lavras Costallat, Simone Appenzeller   +5 more
doaj  

Interferon alpha (IFN-α) in systemic lupus erythematosus (SLE)

Journal of Education, Health and Sport, 2022
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology. An important role in the pathogenesis of SLE has been attributed to interferon alpha (IFN-α), which stimulates the expression of numerous genes, resulting in an increased ...
Sara Moqbil, Eryk Mikos, Joanna Dmochowska, Aleksandra Wójcik, Milena Leziak   +4 more
doaj   +1 more source

Eccrine porocarcinoma of the head: An important differential diagnosis in the elderly patient [PDF]

, 2008
Background: Eccrine porocarcinoma is a rare malignant tumor of the sweat gland, characterized by a broad spectrum of clinicopathologic presentations. Surprisingly, unlike its benign counterpart eccrine poroma, eccrine porocarcinoma is seldom found in ...
Akiyoshi E, Brenn T, Cho SB, Daniela Bruch-Gerharz, Dummer R, Goel R, Grimme H, Gunhan, Gutermuth J, Helmke B, Klaus-Werner Schulte, Lan CC, Matloub HS, Mishima Y, Perna C, Peter Arne Gerber, Pinkus H, Plunkett TA, Puttick L, Ritter AM, Robson A, Shaw M, Sigal R, Thomas Ruzicka, Valverde K, Wittenberg GP   +25 more
core   +1 more source